^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Chordoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB567 - Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft
Published date:
03/09/2022
Excerpt:
In the tazemetostat treated PDX model harboring a PBRM1 variant, an overall survival of 100% was observed….Our panel of chordoma PDXs represents a useful preclinical tool for both pharmacologic and biological assessments. The first demonstration of a high antitumor activity of tazemetostat in a PDX model harboring a PBRM1 variant supports further evaluation of EZH2-inhibitors in this subgroup of chordomas.
